{"id":55113,"date":"2026-01-22T10:46:58","date_gmt":"2026-01-22T02:46:58","guid":{"rendered":"https:\/\/flcube.com\/?p=55113"},"modified":"2026-01-22T10:46:59","modified_gmt":"2026-01-22T02:46:59","slug":"novavax-licenses-matrix-m-adjuvant-to-pfizer-in-530m-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55113","title":{"rendered":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal"},"content":{"rendered":"\n<p><strong>Novavax, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVAX:NASDAQ\">NASDAQ:\u202fNVAX<\/a>) entered into a <strong>license agreement<\/strong> with <strong>Pfizer Inc.<\/strong> for <strong>non\u2011exclusive rights<\/strong> to use Novavax\u2019s <strong>Matrix-M adjuvant<\/strong> in up to <strong>two disease area<\/strong>s, receiving an <strong>upfront payment of USD\u202f30\u202fmillion<\/strong> and potential <strong>milestones up to USD\u202f500\u202fmillion<\/strong>, plus <strong>tiered mid\u2011single\u2011digit royalties<\/strong> on product sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Novavax, Inc. (Nasdaq:\u202fNVAX)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Pfizer Inc.<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>Matrix-M adjuvant<\/td><\/tr><tr><td><strong>License Type<\/strong><\/td><td>Non\u2011exclusive<\/td><\/tr><tr><td><strong>Disease Areas<\/strong><\/td><td>Up to 2 (unspecified)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD\u202f30\u202fmillion<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD\u202f500\u202fmillion (development and sales)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered mid\u2011single\u2011digit percentage on net sales<\/td><\/tr><tr><td><strong>Responsibilities<\/strong><\/td><td>Pfizer: development &amp; commercialization; Novavax: supply of Matrix-M<\/td><\/tr><tr><td><strong>Agreement Date<\/strong><\/td><td>20\u202fJan\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-matrix-m-adjuvant\">Technology Profile: Matrix-M Adjuvant<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Saponin-based adjuvant<\/strong> derived from <strong>Quillaja saponaria<\/strong> bark extract, formulated with <strong>cholesterol and phospholipid<\/strong> nanoparticles<\/li>\n\n\n\n<li><strong>Function:<\/strong> Stimulates <strong>broader and stronger immune responses<\/strong> by enhancing <strong>antigen presentation<\/strong>, <strong>T\u2011cell activation<\/strong>, and <strong>antibody production<\/strong><\/li>\n\n\n\n<li><strong>Applications:<\/strong> Currently used in <strong>Novavax COVID\u201119 vaccine<\/strong> and <strong>flu vaccine<\/strong>; proven <strong>safety profile<\/strong> in >100\u202fmillion doses<\/li>\n\n\n\n<li><strong>Advantage:<\/strong> <strong>Well\u2011characterized<\/strong>, <strong>scalable manufacturing<\/strong>, and <strong>compatible with multiple vaccine platforms<\/strong> (protein, mRNA, viral vectors)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-financial-outlook\">Market Impact &amp; Financial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Vaccine Adjuvant Market<\/th><th>Pfizer Vaccine Portfolio<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Adjuvant Market (2026E)<\/strong><\/td><td>$1.2\u202fbillion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Matrix\u2011M Revenue (Novavax, 2025)<\/strong><\/td><td>$420\u202fmillion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Pfizer License Value (Upfront)<\/strong><\/td><td>USD\u202f30\u202fmillion<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to USD\u202f530\u202fmillion<\/strong><\/td><td>\u2013<\/td><\/tr><tr><td><strong>Royalty Tier<\/strong><\/td><td>Mid\u2011single\u2011digit (est. 4\u20116%)<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Pfizer Disease Areas (Est.)<\/strong><\/td><td>\u2013<\/td><td>Oncology, infectious disease<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Accretion:<\/strong> Upfront payment provides <strong>immediate cash<\/strong> to Novavax; milestones and royalties offer <strong>long\u2011term upside<\/strong> as Pfizer advances candidate vaccines<\/li>\n\n\n\n<li><strong>Supply Agreement:<\/strong> Novavax will be <strong>sole supplier<\/strong> of Matrix-M for Pfizer\u2019s licensed products, securing <strong>recurring revenue stream<\/strong><\/li>\n\n\n\n<li><strong>Scalability:<\/strong> Novavax\u2019s <strong>Matrix\u2011M manufacturing facility<\/strong> (capacity 2\u202fbillion doses\/year) can support Pfizer\u2019s commercial demand<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning\">Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Novavax:<\/strong><\/li>\n\n\n\n<li><strong>Validates Matrix\u2011M platform<\/strong> beyond COVID\u201119, demonstrating <strong>broad utility<\/strong> for partners<\/li>\n\n\n\n<li><strong>Non\u2011dilutive funding<\/strong> supports <strong>pipeline expansion<\/strong> (e.g., combo flu\u2011COVID vaccine, malaria vaccine)<\/li>\n\n\n\n<li><strong>Royalty stream<\/strong> provides <strong>steady revenue<\/strong> independent of Novavax\u2019s own product sales<\/li>\n\n\n\n<li><strong>For Pfizer:<\/strong><\/li>\n\n\n\n<li><strong>Access to proven adjuvant<\/strong> accelerates <strong>vaccine development timeline<\/strong> by <strong>12\u201118 months<\/strong> vs. internal adjuvant development<\/li>\n\n\n\n<li><strong>Subcutaneous delivery<\/strong> potential for <strong>large\u2011volume biologics<\/strong> (e.g., monoclonal antibodies)<\/li>\n\n\n\n<li><strong>Cost\u2011effective licensing<\/strong> vs. acquiring adjuvant company outright<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding milestone achievements, royalty forecasts, and supply chain scalability. Actual results may differ due to Pfizer\u2019s development decisions, competitive dynamics in the adjuvant market, and manufacturing capacity constraints.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2631,800,309,12],"class_list":["post-55113","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-nasdaq-nvax","tag-novavax","tag-pfizer","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55113\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal\" \/>\n<meta property=\"og:description\" content=\"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55113\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T02:46:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T02:46:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal\",\"datePublished\":\"2026-01-22T02:46:58+00:00\",\"dateModified\":\"2026-01-22T02:46:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113\"},\"wordCount\":407,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"NASDAQ: NVAX\",\"Novavax\",\"Pfizer\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55113#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55113\",\"name\":\"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T02:46:58+00:00\",\"dateModified\":\"2026-01-22T02:46:59+00:00\",\"description\":\"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55113\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55113#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55113","og_locale":"en_US","og_type":"article","og_title":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal","og_description":"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.","og_url":"https:\/\/flcube.com\/?p=55113","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T02:46:58+00:00","article_modified_time":"2026-01-22T02:46:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55113#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55113"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal","datePublished":"2026-01-22T02:46:58+00:00","dateModified":"2026-01-22T02:46:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55113"},"wordCount":407,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["NASDAQ: NVAX","Novavax","Pfizer","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55113#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55113","url":"https:\/\/flcube.com\/?p=55113","name":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T02:46:58+00:00","dateModified":"2026-01-22T02:46:59+00:00","description":"Novavax, Inc. (NASDAQ:\u202fNVAX) entered into a license agreement with Pfizer Inc. for non\u2011exclusive rights to use Novavax\u2019s Matrix-M adjuvant in up to two disease areas, receiving an upfront payment of USD\u202f30\u202fmillion and potential milestones up to USD\u202f500\u202fmillion, plus tiered mid\u2011single\u2011digit royalties on product sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55113#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55113"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55113#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novavax Licenses Matrix-M Adjuvant to Pfizer in $530M Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55113"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55113\/revisions"}],"predecessor-version":[{"id":55114,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55113\/revisions\/55114"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}